RhumbLine Advisers’s Neuropace NPCE Stock Holding History

RhumbLine Advisers’s Portfolio NPCE Stock Details NPCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$442K	Buy	32,110 +446	+1%	+$6.61K	﹤0.01%	2811
2026 Q2	$503K	Buy	31,664 +2,218	+8%	+$35.7K	﹤0.01%	2765
2026 Q1	$387K	Buy	29,446 +139	+0.5%	+$2.08K	﹤0.01%	2768
2025 Q4	$452K	Sell	29,307 -2,726	-9%	-$36.5K	﹤0.01%	2732
2025 Q3	$330K	Sell	32,033 -4,923	-13%	-$46.4K	﹤0.01%	2930
2025 Q2	$412K	Buy	36,956 +19,729	+115%	+$247K	﹤0.01%	2802
2025 Q1	$212K	Buy	17,227 +2,267	+15%	+$28.4K	﹤0.01%	3078
2024 Q4	$167K	Buy	14,960 +634	+4%	+$5.51K	﹤0.01%	3284
2024 Q3	$100K	Sell	14,326 -338	-2%	-$2.47K	﹤0.01%	3495
2024 Q2	$111K	Buy	+14,664	New	+$148K	﹤0.01%	3489

Other funds holding NPCE

Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Essex Investment Management Boston, Massachusetts $675M AUM 61.81% 1-Year Est. Return

Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return

Legato Capital Management San Francisco, California $1.11B AUM 60.78% 1-Year Est. Return

Russell Investments Group London, United Kingdom $114B AUM 33.83% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

SEI Investments Oaks, Pennsylvania $113B AUM 26.61% 1-Year Est. Return

Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return

Squarepoint New York $90.8B AUM 26.98% 1-Year Est. Return

RhumbLine Advisers's NPCE Position: Q3 2026 in Review

RhumbLine Advisers increased its Neuropace (NPCE) stake by 1.4% in Q3 2026, buying an estimated $6.61K and bringing the position to 32,110 shares worth $442K. The position accounts for ﹤0.01% of the portfolio, ranked #2811.

RhumbLine Advisers first reported a position in NPCE in Q2 2024 and has held it in 10 quarters since. The position peaked at $503K in Q2 2026. 39 funds tracked by Wall St. Rank hold NPCE as of Q3 2026.

RhumbLine Advisers held 32,110 shares of Neuropace worth $442K as of Q3 2026.
RhumbLine Advisers bought 446 Neuropace shares in Q3 2026, an estimated $6.61K.
Neuropace made up ﹤0.01% of RhumbLine Advisers's portfolio in Q3 2026, its #2811 holding.
RhumbLine Advisers first reported a position in Neuropace in Q2 2024 and has held it in 10 quarters since.
RhumbLine Advisers's Neuropace position peaked at $503K in Q2 2026.
39 funds tracked by Wall St. Rank held Neuropace as of Q3 2026.

Based on RhumbLine Advisers's 13F filing for Q3 2026, filed 10 Nov 2026.